Organoid models of ovarian cancer: resolving immune mechanisms of metabolic reprogramming and drug resistance
Metabolic reprogramming is a hallmark of ovarian cancer, enabling tumor progression, immune evasion and drug resistance. The tumor microenvironment (TME) further shapes metabolic adaptations, enabling cancer cells to withstand hypoxia and nutrient depr…